company background image
CU6

Clarity Pharmaceuticals ASX:CU6 Stock Report

Last Price

AU$0.84

Market Cap

AU$218.1m

7D

-5.1%

1Y

14.3%

Updated

29 Jan, 2023

Data

Company Financials +

Clarity Pharmaceuticals Ltd

ASX:CU6 Stock Report

Mkt Cap: AU$218.1m

CU6 Stock Overview

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults.

CU6 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Clarity Pharmaceuticals Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Clarity Pharmaceuticals
Historical stock prices
Current Share PriceAU$0.84
52 Week HighAU$1.05
52 Week LowAU$0.36
Beta0
1 Month Change-15.15%
3 Month Change21.74%
1 Year Change14.29%
3 Year Changen/a
5 Year Changen/a
Change since IPO-44.00%

Recent News & Updates

Recent updates

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Aug 24
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Jan 13
Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Shareholder Returns

CU6AU PharmaceuticalsAU Market
7D-5.1%-4.4%0.6%
1Y14.3%-25.2%3.5%

Return vs Industry: CU6 exceeded the Australian Pharmaceuticals industry which returned -25.2% over the past year.

Return vs Market: CU6 exceeded the Australian Market which returned 3.5% over the past year.

Price Volatility

Is CU6's price volatile compared to industry and market?
CU6 volatility
CU6 Average Weekly Movement9.1%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement8.5%
10% most volatile stocks in AU Market15.7%
10% least volatile stocks in AU Market3.5%

Stable Share Price: CU6 is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CU6's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010n/aColin Bigginhttps://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen.

Clarity Pharmaceuticals Ltd Fundamentals Summary

How do Clarity Pharmaceuticals's earnings and revenue compare to its market cap?
CU6 fundamental statistics
Market CapAU$218.12m
Earnings (TTM)-AU$23.75m
Revenue (TTM)AU$6.46m

33.8x

P/S Ratio

-9.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CU6 income statement (TTM)
RevenueAU$6.46m
Cost of RevenueAU$0
Gross ProfitAU$6.46m
Other ExpensesAU$30.21m
Earnings-AU$23.75m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.091
Gross Margin100.00%
Net Profit Margin-367.78%
Debt/Equity Ratio0%

How did CU6 perform over the long term?

See historical performance and comparison